Where might the AstraZeneca share price go in 2025? Here’s what the experts forecast

The AstraZeneca share price is down almost 20% since September! What’s behind this drop, and where do analysts think the stock’s heading in 2025?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2024s been a bit of a rollercoaster ride for the AstraZeneca (LSE:AZN) share price. Continued success at the clinical level has allowed the pharma giant to continue growing at an impressive pace. And earlier this year, the business outlined its new ambition to reach over $80bn (£63.2bn) in sales by 2030.

The result of this was a 30% increase in the stock price between January and September. But in the months since, AstraZeneca shares have given back almost all of these gains. What happened? And where do the experts think the AstraZeneca share price is heading in 2025?

Trouble in China

2024 has been a bit of a purge for China. Authorities have been cracking down on corruption in the private sector, with a lot of foreign companies getting targeted by regulatory probes. That includes AstraZeneca, whose China president, Leon Wang, was officially detained at the end of October.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

There’s very little information surrounding this ongoing situation. However, it’s speculated that it could be linked to an ongoing investigation into medical insurance fraud. Already, around 100 ex-employees have been sentenced to prison. And if Wang’s found to be complicit, it could spell a lot of trouble ahead.

Wang first joined AstraZeneca in early 2013. Since then, operations in China have boomed. His strategy has largely focused on localising the supply chain and investing in local startups researching breakthrough therapies.

This granted the firm a more dominant position in the second-largest healthcare market worldwide after the United States. That’s particularly important since China also has an estimated 43% of global lung cancer cases as a result of high air pollution and smoking. Don’t forget AstraZeneca has a huge cancer therapy portfolio. And strong demand from China is a key part of its $80bn revenue target.

With Wang being detained, all of that is now in question. And since shareholders hate uncertainty, it isn’t surprising the AstraZeneca share price has taken a double-digit tumble.

What do the analysts think?

Looking at the latest forecasts, opinions appear to be mixed. The most optimistic outlook, which likely assumes everything in China will be resolved favourably, indicates a potential +70% upside, reaching 18,115p by this time next year. However, should the Chinese probe evolve into criminal charges across AstraZeneca’s executive team, then the stock could collapse by as much as 40%, falling to 6,321p.

China may only contribute around 13% of revenue today. However, it represents a large part of the firm’s long-term growth potential. And an adversarial relationship with Chinese authorities will likely make it very difficult to tap into this massive market.

Still, outside of China, the business appears to be performing well, receiving new regulatory approvals and a steady stream of encouraging clinical trial results. Does that make it a good stock to buy today?

For the long run, I remain optimistic. However, investors seeking to capitalise on the recent share price dip will likely have to brace for more volatility if the situation in China escalates. Personally, I’m going to wait and see how this all turns out before exposing my portfolio to this risk.

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won't want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we're giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: 12 months from now, £5,000 invested in Tesla stock could be worth…

Tesla stock has endured a miserable year so far, falling by 29%. Muhammad Cheema takes a look at how it…

Read more »

Investing Articles

See what £10,000 invested in Tesla shares at their mid-December peak is worth today 

As the world absorbs the full scale of Donald Trump's tariffs, Tesla shares are reeling. Investors who bought the stock…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Dividend Shares

2 ‘safe’ LSE dividend stocks to consider as global markets sell off

As global markets experience high levels of volatility due to economic uncertainty, investors are piling into these ‘safe-haven’ dividend stocks.

Read more »

Investing Articles

US stock market rout: an unmissable opportunity for investors?

His tech-heavy portfolio has been smashed by Trump’s tariffs. However, Dr James Fox believes there could be some opportunities in…

Read more »

Investing Articles

After a 13% ‘Trump tariff’ fall, is the Barclays share price too cheap to miss?

Does the Barclays share price fall mean we should all panic and run screaming from the stock market? Nah, of…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

2 investment trusts to consider for a Stocks and Shares ISA

These two investment trusts have a different focus -- but our writer sees both as worth considering, one more for…

Read more »

Investing Articles

Deutsche Bank reiterates Buy rating on 9.6% yielding FTSE 250 stock that was “most shorted in UK”

Our writer investigates why a major broker remains optimistic about a FTSE 250 stock that was once the most shorted…

Read more »

Investing Articles

2 things to remember when stock markets are turbulent

US trade policy has rattled the stock markets in New York, London and elsewhere. Our writer outlines a couple of…

Read more »